Abstract |
Hepatocellular carcinoma (HCC) is one of the commonest lethal malignancies worldwide, and often diagnosed at an advanced stage, without any curative therapy. Immune checkpoint blockers targeting the programmed death receptor 1 (PD-1) have shown impressive antitumor activity in patients with advanced-stage HCC, while the response rate is only 30%. Inducible PD-L1 overexpression may result in a lack of response to cancer immunotherapy, which is attributed to a mechanism of adaptive immune resistance. Our study investigated that the overexpression of PD-L1 promoted the invasion and migration of liver cancer cells in vitro, and the induced overexpression of PD-L1 in the tumor microenvironment could weaken the effects of anti-PD-1 immunotherapy in a BALB/c mouse model of liver cancer. CPI-203, a small-molecule bromodomain-containing protein 4 (BRD4) inhibitor, which can potently inhibit PD-L1 expression in vitro and in vivo, combined with PD-1 antibody improved the response to immunotherapy in a liver cancer model. Cell transfection and chromatin immunoprecipitation assay manifested that BRD4 plays a key role in PD-L1 expression; CPI-203 can inhibit PD-L1 expression by inhibiting the BRD4 occupation of the PD-L1 promoter region. This study indicates a potential clinical immunotherapy method to reduce the incidence of clinical resistance to immunotherapy in patients with HCC.
|
Authors | Xiaoge Niu, Wei Wang, Taizhen Liang, Shasha Li, Chan Yang, Xinfeng Xu, Lin Li, Shuwen Liu |
Journal | Cancer science
(Cancer Sci)
Vol. 113
Issue 1
Pg. 28-40
(Jan 2022)
ISSN: 1349-7006 [Electronic] England |
PMID | 34727389
(Publication Type: Journal Article)
|
Copyright | © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |
Chemical References |
- Acetamides
- Azepines
- B7-H1 Antigen
- BRD4 protein, human
- CD274 protein, human
- CPI203
- Cell Cycle Proteins
- Immune Checkpoint Inhibitors
- Transcription Factors
|
Topics |
- Acetamides
(administration & dosage, pharmacology)
- Animals
- Azepines
(administration & dosage, pharmacology)
- B7-H1 Antigen
(genetics)
- Cell Cycle Proteins
(metabolism)
- Cell Line, Tumor
- Drug Synergism
- Gene Expression Regulation, Neoplastic
(drug effects)
- Hep G2 Cells
- Humans
- Immune Checkpoint Inhibitors
(administration & dosage, pharmacology)
- Lung Neoplasms
(drug therapy, genetics, metabolism)
- Male
- Mice
- Promoter Regions, Genetic
(drug effects)
- Transcription Factors
(metabolism)
- Tumor Escape
(drug effects)
- Tumor Microenvironment
(drug effects)
- Up-Regulation
(drug effects)
- Xenograft Model Antitumor Assays
|